abstract |
The present invention relates to an anticancer composition comprising a tumor-specific killing adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus of the present invention introduced with IL-12 and shVEGF exhibits excellent anticancer effect by improving immune function, and it was confirmed that this anticancer effect was remarkably enhanced through combination with an immune checkpoint inhibitor, the present invention can be utilized as a core technology in the field of cancer treatment. |